Sebastian Szmit: Advances in Managing Cancer-Associated Thromboembolism
OncoDaily shared on LinkedIn:
”Dr. Sebastian Szmit Highlights Advances in Managing Cancer-Associated Thromboembolism at GCOS 2025
Dr. Sebastian Szmit, from the Institute of Hematology and Transfusion Medicine and the Center of Postgraduate Medical Education in Warsaw, delivered an engaging talk on cancer-associated thromboembolism. He discussed premature mortality linked to VTE in cancer patients and reviewed ESC guideline–based anticoagulation options, comparing DOACs (apixaban, edoxaban, rivaroxaban) with low-molecular-weight heparin (LMWH). He emphasized that while DOACs are effective, LMWH remains preferred in gastrointestinal cancers due to higher bleeding risks.
Dr. Szmit also presented findings from the APICAT study, which showed that a reduced dose of apixaban can maintain efficacy while lowering bleeding risk during extended anticoagulation. He highlighted challenges such as drug interactions, thrombocytopenia, and the need for improved primary prophylaxis strategies tailored to cancer therapy.”
Stay informed with Hemostasis Today.
-
Aug 21, 2026, 21:58Toby Richards: WEHI Trial Solidifies IV Iron as Third-Trimester Standard
-
Aug 21, 2026, 21:51Mehak Trehan: From Reading the Chapter to Writing One
-
Aug 21, 2026, 21:38Ann Reilly: Navigating Postoperative vs. Acute Blood Loss Anemia – A CDI Case Study
-
Aug 21, 2026, 21:29Merlin Crossley: Atomic Precision in Sickle Cell Care – Structural Targeting for Fetal Globin Reactivation
-
Aug 21, 2026, 19:09Aphisit Thongthaisin: Admitted to Sorbonne University’s T2H University Diploma for 2026/2027
-
Aug 21, 2026, 19:07José Luis Ferreiro Gutiérrez: Proud to Be Elected Chairperson-Elect of the ESC Working Group on Thrombosis
-
Aug 21, 2026, 19:00Manuel Monreal: New RIETE Registry Data on VTE Recurrence and Bleeding During Anticoagulation
-
Aug 21, 2026, 18:39Ronak H. Mistry: Updated ASH ITP Guidelines Bring New Guidance for Managing ITP
-
Aug 21, 2026, 18:22Ahmed Bennis: NOAC Use Is Associated With Slower Cognitive Decline in AF and Alzheimer’s Disease